XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Influenza Channel
subscribe to Influenza newsletter

Latest Research : Infectious Diseases : Influenza

   DISCUSS   |   EMAIL   |   PRINT
Low Dose Oral Interferon Alfa-n3 May Serve as a Potential Therapy for Avian Flu
Mar 24, 2005, 09:33, Reviewed by: Dr.

The multiple actions of cocktails of material human alpha interferons is the crux of Hemispherx's belief that Low Dose Oral Interferon Alfa-n3 (already FDA-approved for treatment of human papilloma virus) may be able to inactivate avian influenza by boosting the immune system of both birds raised as poultry crop so as to prevent infection, as well as act as both a short-term immune boost lending to a long-term vaccine-like protection in humans.

 
Hemispherx Biopharma, Inc. continues the evaluation of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) as a potential therapy for Avian Flu.

The anticipated clinical trials in human volunteers (to be conducted in both the U.S. and Asia) are designed to determine whether Low Dose Oral Interferon Alfa-n3, delivered in a new, experimental oral drug delivery format, can resuscitate the broad-spectrum antiviral genes, which are shut down by dreaded viruses such as avian flu and smallpox.

Considering today's announcement of a "risky" experiment by the Centers for Disease Control and Prevention to simulate the mixing and matching of genes from the avian flu virus and a common human flu into a pandemic, Hemispherx's upcoming human trials are more necessary than ever.

With the World Health Organization predicting that the avian flu threatens to spread around the world and infect millions of people, Hemispherx Biopharma is one of a few companies evaluating a potential treatment for the deadly virus in a safely designed and controlled environment.

The multiple actions of cocktails of material human alpha interferons is the crux of Hemispherx's belief that Low Dose Oral Interferon Alfa-n3 (already FDA-approved for treatment of human papilloma virus) may be able to inactivate avian influenza by boosting the immune system of both birds raised as poultry crop so as to prevent infection, as well as act as both a short-term immune boost lending to a long-term vaccine-like protection in humans.

Initial studies indicate that alpha interferons stimulate broad-spectrum antiviral and immune system genes when given by injection, but such studies have not yet been systematically controlled by oral delivery.

With the lack of any currently available treatment for Avian Flu in the marketplace, as well as the potential for a "global pandemic" anticipated by many if the virus mutates and transfers from animals to humans, Hemispherx is a drug manufacturer with a novel approach to battling Avian Flu: Tested in the food and water of birds raised as poultry crops (where the virus may breed) the company has found that Low Dose Oral Interferon Alfa-n3 may reduce mortality rates and may contribute to a healthier bird population.

Additionally, and very importantly, Hemispherx is set to begin drug trials in humans within the month looking at relevant gene activation profiles.

Recent studies indicate that these disabled genes may have led to the pandemic in 1918/1919, which killed millions around the globe.
 

- Hemispherx Biopharma
 

Hemispherx Biopharma

 
Subscribe to Influenza Newsletter
E-mail Address:

 

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities. Its flagship products include Alferon N(R) and the experimental antiviral products, Ampligen(R) and Oragens(TM). These novel Alferon-N proteins, commercially available for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its four major technology platforms include large-and small-agent components for potential treatment of various chronic viral infections, and are being developed with various corporate, governmental and academic collaborators worldwide. Hemispherx has more than 200 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit the company's website.

Related Influenza News

Are influenza vaccines worth the effort?
Oseltamivir significantly reduces the risk of death from influenza
Prisons Unprepared for Flu Pandemic
University of Pittsburgh receives $1.3 million grant for developing a promising avian flu vaccine
Novel DNA-Based H5N1(Avian) influenza vaccine
Genetic differences between potential pandemic influenza strains outlined
Avian flu virus needs only minor adaptations to infect humans
Influenza-Associated Hospitalization in a Subtropical City
SRL Ranbaxy offers a quicker bird flu diagnostic test
Bird flu vaccine may be fruitless


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us